In June 2021, the healthcare industry reported 106 deals worth $49.7 billion as compared to the last 12-month average (June 2020 to May 2021) of 104 deals worth $23.4 billion.

Hellman & Friedman LLC; The Blackstone Group Inc; The Carlyle Group Inc.; GIC Pvt Ltd to acquire a majority stake in Medline Industries Inc. for a consideration of approximately $34 billion was the big-ticket deal, which contributed 68.4 per cent of the total deal value in June 2021. Other top deals during the period were Danaher Corporation to acquire Aldevron LLC, a manufacturer and supplier of plasmid DNA (deoxyribonucleic acid), proteins, enzymes, antibodies, and other biologicals for $9.4 billion and MorphoSys AG, a commercial-stage biopharmaceutical company to acquire Constellation Pharmaceuticals Inc, a clinical-stage biopharmaceutical company developing novel therapeutics, which selectively modulate gene expression to address serious unmet medical needs in patients with cancer for $1.7 billion.

VC investments decreased by six per cent in June 2021, compared to May 2021

The health supplies industry reported 139 venture capital (VC) deals worth $4.5 billion in June 2021, compared to the last 12-month average (June 2020 to May 2021) of 166 deals worth $4.9 billion.

InSilico Medicine Inc, raising $255 million to progress its current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities; Umoja BioPharma Inc, an oncology company raising $210 million Series B financing to continue development of its integrated technologies, advance its product candidates based on CAR T-cell adapter-mediated tumor-targeting (TumorTag) and the in vivo modification of immune cells (VivoVec and RACR/CAR) into clinical development; and Stemirna Therapeutics Ltd, raising $200 million to finance clinical trials and production of its COVID-19 vaccine development are the major VC deals reported in May 2021.